Document:

Exhibit 10.15

 

		Notice of Award	
	SMALL BUSINESS INNOVATION RESEARCH PROG           Issue Date:       07/31/2013
	Department of Health and Human Services

National Institutes of Health
	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES

 

Grant Number: 5R44DK066654-06 REVISED

 

Principal Investigator(s):

WEIZHONG CAI, PHD

 

Project Title: Pilot Clinical Study in Renal
Transplantation

 

Dr. Goldberg, Itzhak D.

President & Scientific Director

1050 Stewart
Ave.

Garden City, NY 11530

 

Award e-mailed to: igoldberg@angion.com

 

Budget Period: 08/01/2010 – 07/31/2014

Project Period: 05/01/2004 – 07/31/2014

 

Dear Business Official:

 

The National Institutes of Health hereby revises
this award (see “Award Calculation” in Section I and “Terms and Conditions” in Section III) to ANGION BIOMEDICA
CORPORATION in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 15 USC 638 42 CFR
52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and
conditions.

 

Acceptance of this award including the “Terms
and Conditions” is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

 

Each publication, press release, or other document
about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as “Research
reported in this publication was supported by the National Institute Of Diabetes And Digestive And Kidney Diseases of the National
Institutes of Health under Award Number R44DK066654. The content is solely the responsibility of the authors and does not necessarily
represent the official views of the National Institutes of Health.” Prior to issuing a press release concerning the outcome
of this research, please notify the NIH awarding IC in advance to allow for coordination.

 

Award recipients must promote objectivity in research
by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under
NIH awards will be free from bias resulting from an Investigator’s Financial Conflict of Interest (FCOI), in accordance
with 42 CFR Part 50 Subpart F. Subsequent to the compliance date of the 2011 revised FCOI regulation (i.e., on or before August
24, 2012), Awardees must be in compliance with all aspects of the 2011 revised regulation; until then, Awardees must comply with
the 1995 regulation. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation
does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult
the NIH website http://grants.nih.gov/grants/policy/coi/ for a link to the regulation and additional important information.

 

If you have any questions about this award, please
contact the individual(s) referenced in Section IV.

 

Sincerely yours,

 

CAROLYN KOFA

Grants Management Officer

NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND
KIDNEY DISEASES

 

	1	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

 

    	 

    	 

    

  

Additional information follows

 

	2	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

 

 

    	 

    	 

    

 

 

	 	SECTION I – AWARD DATA – 5R44DK066654-06 REVISED

 

	Award
    Calculation (U.S. Dollars)	 	 	 
	 	 	 	 
	Federal Direct Costs	 	$	[***]	 
	Federal F&A Costs	 	$	[***]	 
	Approved Budget	 	$	[***]	 
	Fee	 	$	[***]	 
	Federal Share	 	$	[***]	 
	TOTAL FEDERAL AWARD AMOUNT	 	$	822,071	 
	 	 	 	 	 
	AMOUNT OF THIS ACTION (FEDERAL SHARE)	 	$	0	 

 

	SUMMARY
    TOTALS FOR ALL YEARS	 
	YR	 	THIS
    AWARD	 	 	CUMULATIVE
    TOTALS	 
	6	 	$	822,071	 	 	$	822,071	 

 

	Fiscal Information:	 
	CFDA Number:	93.847
	EIN:	1113430072A1
	Document Number:	RDK066654C
	Fiscal Year:	2010

 

	IC	 	CAN	 	2010	 
	DK	 	8469933	 	$	822,071	 

 

NIH Administrative Data:

PCC: KMM KSB / OC: 414E / Released:
KOFAC 07/30/2013

Award Processed: 07/31/2013 12:11:51 AM

 

	 	SECTION II – PAYMENT/HOTLINE INFORMATION – 5R44DK066654-06 REVISED

 

For payment and HHS Office of Inspector General
Hotline information, see the NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm

 

	 	SECTION III – TERMS AND CONDITIONS – 5R44DK066654-06 REVISED

 

This award is based on the application submitted
to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly
or by reference in the following:

 

		a.	The grant program legislation and program regulation cited
in this Notice of Award.

		b.	Conditions on activities and expenditure of funds in other
statutory requirements, such as those included in appropriations acts.

		c.	45 CFR Part 74 or 45 CFR Part 92 as applicable.

		d.	The NIH Grants Policy Statement, including addenda in effect
as of the beginning date of the budget period.

		e.	This award notice, INCLUDING THE TERMS AND CONDITIONS CITED
BELOW.

 

(See NIH Home Page at ‘http://grants.nih.gov/grants/policy/awardconditions.htm’
for certain references cited above.)

 

An unobligated balance may be carried over into
the next budget period without Grants Management Officer prior approval.

 

This grant is subject to Streamlined Noncompeting
Award Procedures (SNAP).

 

In accordance with P.L. 110-161, compliance with
the NIH Public Access Policy is now mandatory.

 

	 	3	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

 

  

    	 

    	 

    

 

For more information, see NOT-OD-08-033 and the
Public Access website: http://publicaccess.nih.gov/.

 

This award provides support for one or more clinical
trials. By law (Title VIII, Section 801 of Public Law 110-85), the “responsible party” must register “applicable
clinical trials” on the ClinicalTrials.gov Protocol Registration System Information Website. NIH encourages registration
of all trials whether required under the law or not. For more information, see http://grants.nih.gov/ClinicalTrials_fdaaa/

 

This award represents the final year of the competitive
segment for this grant. See the NIH Grants Policy Statement Section 8.6 Closeout for complete closeout requirements at: http://grants.nih.gov/grants/policy/#gps
..

 

A final Federal Financial Report (FFR) (SF 425)
must be submitted through the eRA Commons (Commons) within 90 days of the expiration date; see the NIH Grants Policy Statement
Section 8.6.1 Financial Reports, http://grants.nih.gov/grants/policy/#gps, for additional information on this submission
requirement. The final FFR must indicate the exact balance of unobligated funds and may not reflect any unliquidated obligations.
There must be no discrepancies between the final FFR expenditure data and the Payment Management System’s (PMS) cash transaction
data.

 

A Final Invention Statement and Certification form
(HHS 568), (not applicable to training, construction, conference or cancer education grants) must be submitted within 90 days of
the expiration date. The HHS 568 form may be downloaded at: http://grants.nih.gov/grants/forms.htm.

 

Unless an application for competitive renewal is
submitted, a final progress report must also be submitted within 90 days of the expiration date. Instructions for preparing a Final
Progress Report are at: http://grants.nih.gov/grants/funding/finalprogressreport.pdf. Any other specific requirements set forth
in the terms and conditions of the award must also be addressed in the final progress report. Institute/Centers may accept the
progress report contained in competitive renewal (type 2) in lieu of a separate final progress report. Contact the awarding IC
for IC- specific policy regarding acceptance of a progress report contained in a competitive renewal application in lieu of a separate
final progress report.

 

NIH strongly encourages electronic submission
of the final progress report and the final invention statement through the Closeout feature in the Commons, but will accept an
email or hard copy submission as indicated below.

 

Email: The final progress report and final invention
statement may be e-mailed as PDF attachments to the NIH Central Closeout Center at: DeasCentralized@od.nih.gov.

 

Hard copy: Paper submissions of the final progress
report and the final invention statement may be faxed to the NIH Division of Central Grants Processing at 301-480-2304, or mailed
to:

 

NIH Division of Central Grants Processing, OER

6705
Rockledge Drive

Suite 5016, Room 5109

MSC 7986

Bethesda, MD 20892-7986 (for regular or U.S. Postal
Service Express mail)

Bethesda, MD 20817 (for other courier/express mail delivery only)

 

NOTE: If this is the final year of a competitive
segment due to the transfer of the grant to another institution, then a Final Progress Report is not required. However, a final
FFR is required and should be submitted electronically as noted above. If not already submitted, the Final Invention Statement
is required and should be sent directly to the assigned Grants Management Specialist.

 

Treatment of Program Income:

Additional Costs

 

	 	SECTION IV – DK Special Terms and Conditions – 5R44DK066654-06 REVISED

 

REVISION #2:

Revised award issued to extend the budget and project
period for an additional 12 months duation, ending July 31, 2014, as requested in the
grantee’s letter dated June 24, 2013.

 

	 	4	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

 

    	 

    	 

    

 

THE FOLLOWING TERMS FROM THE PREVIOUS NOTICE OF AWARD
ISSUED ON MAY 24, 2012, ALSO APPLY TO THIS AWARD:

 

REVISION #1:

Revised award issued to extend the budget and project
period for an additional 12 months duation, ending July 31, 2013, as requested by the grantee.

 

This revised award also reflects the NIDDK’s receipt
and acceptance of the grantee’s notification, certifying IRB approval on January 27, 2010. Accordingly, the restriction prohibiting
research involving human subjects on the Notice of Award issued on September 12, 2010, is removed.

 

No funds may be drawn down from the payment system
and no obligations may be made against Federal funds for research involving human subjects at any site engaged in such research
for any period not covered by an OHRP-approved Assurance and by an IRB approval consistent with 45 CFR Part 46.

 

THE FOLLOWING TERMS FROM THE PREVIOUS NOTICE OF AWARD
ISSUED ON SEPTEMBER 12, 2010, ALSO APPLY TO THIS AWARD:

 

The issuance of this award has been delayed due to
administrative considerations. According to NIH policy, if preaward costs are necessary, they may be approved by the authorized
Institution Official(s).

 

The grantee is required to follow the data and safety
monitoring plan included in the previous application and may not implement any changes in the plan without the written prior approval
of the NIDDK.

 

This award includes funds awarded for consortium
activity with the University of Pittsburg as stated in letter dated 03/29/2010 in the amount of $[***] total cost. Consortiums are
to be established and administered as described in the NIH Grants Policy Statement (NIH GPS). The referenced section of the NIH
Grants Policy Statement is available at http://grants1.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part12.htm#_Toc54600251, pages
224-227.

 

In addition to the PI, the following individuals
are named as key personnel: (Dr. Shapiro)

 

Written prior approval is required if any of the
individual(s) named above withdraws from the project entirely, is absent from the project during any continuous period of 3 months
or more, or reduces time devoted to the project by 25 percent or more from the level that was approved at the time of award.

 

Prior to drawing down funds for this award from the
payment management system, you are required to have in place written policies and procedures for financial and business management
systems. Your systems must comply with the standards included in the attachment to the letter/email “Requirements for Financial
and Business Management Systems Requirements for SBIR/STTR Awardees” which was sent to your organization’s Business Official
on May 20, 2009.

 

The policies and procedures must remain in effect
for the duration of this project.

 

Notice: Under governing regulations, Federal funds
administered by the Department of Health and Human Services shall not be expended for research involving human subjects, and individuals
shall not be enrolled in such research, without prior approval by the Office of Human Research Protections (OHRP) of an assurance
to comply with the requirements of 45 CFR 46 to protect human research subjects. This restriction applies to all collaborating
sites without OHRP- approved assurances, whether domestic or foreign, and compliance must be ensured by the awardee.

 

The fee provided as part of this grant award is in
addition to the allowable direct and indirect costs. An adjustment of the fee will be made in the event the grant is terminated.
The fee should

 

	 	5	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

 

    	 

    	 

    

 

be drawn down from the DHHS Payment Management System
in increments proportional to the draw down of funds for costs. Questions concerning access to the Payment Management System should
be directed to the PMS office (877)614-5533.

 

Allowable costs of activities
conducted by for-profit organizations will be determined by applying the cost principles of the Federal Acquisition Regulation
set forth in 48 CFR, Subpart 31.2. (see http://www.access.gpo.gov/nara/cfr/waisidx_01/48cfr31_01.html)

 

Intellectual property rights: Normally, the awardee
organization retains the principal worldwide patent rights to any invention developed with United States government support. Under
Title 37 Code of Federal Regulations Part 401, the government receives a royalty free license for its use, reserves the right to
require the patent holder to license others in certain circumstances, and requires that anyone exclusively licensed to sell the
invention in the United States must normally manufacture it substantially in the United States.

 

Rights and obligations related to inventions created
or reduced to practice as a result of this award are detailed in 35 U.S.C. 205 and 37 CFR Part 401. These inventions must be reported
to the Extramural Invention Reporting and Technology Resources Branch, OPERA, NIH, 6705 Rockledge Drive, MSC 7980, Bethesda, MD
20892-7980, (301) 435-1986. For additional information, access the NIH link on the interagency Edison web site (www.iedison.gov)
which includes an electronic invention reporting system, reference information and the text to 37 CFR 401.

 

To the extent authorized by 35 U.S.C., Section 205,
the government will not make public any information disclosing an NIH-supported invention for a 4-year period to allow the awardee
organization a reasonable time to file a patent application, nor will the government release any information that is part of that
patent application. Prior approval to implement budgetary and programmatic changes, where required by NIH Policy, (See the NIH
Grants Policy Statement for prior approval requirements at: http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part7.htm#_Toc54600126)
must be obtained in writing from the Grants Management contact shown on this Notice of Award. A letter signed by the Principal
Investigator and a Business Official of the Grantee Institution should include an explanation and justification for the action(s).
Requests may be made via e-mail provided they are routed through these same officials. If there are questions as to whether an
action requires prior approval, contact the Grants Management Specialist.

 

Grantees must access a website to determine which
progress reports are due. The Office of Policy for Extramural Research Administration, OER, National Institutes of Health
(NIH) hosts the website located at: http://era.nih.gov/userreports/pr_due.cfm. Grantees are responsible for periodically
checking the list, which is updated on/around the 30th of each month. In addition to this website, email reminders are sent
to the Principal Investigator.

 

Effective with non-competing progress reports due
on/after October 1, 2004, NIH is centralizing receipt and initial processing of all NIH non-competing progress reports. The new
centralized mailing address for all NIH Institutes/Centers (IC) is now:

 

Division of Extramural
Activities Support, OER

National
Institutes of Health

6705 Rockledge Drive, Room 2207, MSC 7987

Bethesda, MD 20892-7987 (for regular or US Postal
Service Express mail)

Bethesda, MD 20817 (for other courier/express mail delivery only)

Phone Number: (301) 594-6584

 

STAFF CONTACTS

 

The Grants Management Specialist is responsible for
the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions.
The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work
together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should
be submitted in writing to the Grants

 

	 	6	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

    	 

    	 

    

 

Management Specialist. Requests may be made via e-mail.

 

Grants Management Specialist: Charlette Kenley

Email: kenleyc@extra.niddk.nih.gov Phone:
(301) 594-8847 Fax: (301) 480-3504

 

Program Official: Marva M. Moxey-mims

Email: moxey-mimsm@extra.niddk.nih.gov Phone:
(301) 451-5037 Fax: (301) 480-3510

 

	 	7	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

  

    	 

    	 

    

 

SPREADSHEET SUMMARY

GRANT NUMBER: 5R44DK066654-06 REVISED

 

INSTITUTION: ANGION BIOMEDICA CORPORATION

 

	Facilities
    and Administrative Costs	 	Year
    6	 
	F&A Cost Rate 1	 	 	90	%
	F&A Cost Base 1	 	$	[***]	 
	F&A Costs 1	 	$	[***]	 

 

	 	8	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.Exhibit 10.16

 

		Notice of Award	
	SMALL BUSINESS INNOVATION RESEARCH PROG       Issue Date:    03/28/2012
	Department of Health and Human Services 

National Institutes of Health
	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES

 

Grant Number: 5R44DK078455-03

 

Principal Investigator(s):

WEIZHONG CAI, PHD

 

Project Title: Unique Clinical Study on DGF
Using Paired Kidneys

 

Dr. Goldberg, Itzhak D

President & Scientific Director

1050 Stewart Ave.

Garden City, NY 115304888

 

Award e-mailed to: igoldberg@angion.com

 

Budget Period: 04/01/2012 – 03/31/2013

Project Period: 03/01/2007 – 03/31/2013

 

Dear Business Official:

 

The National Institutes of Health hereby awards a
grant in the amount of $664,710 (see “Award Calculation” in Section I and “Terms and Conditions” in Section
III) to ANGION BIOMEDICA CORPORATION in support of the above referenced project. This award is pursuant to the authority of 42
USC 241 42 CFR PART 52 15 USC 638 and is subject to the requirements of this statute and regulation and of other referenced, incorporated
or attached terms and conditions.

 

Acceptance of this award including the “Terms
and Conditions” is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

 

Each publication, press release, or other document
about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as “Research
reported in this publication was supported by the National Institute Of Diabetes And Digestive And Kidney Diseases of the National
Institutes of Health under Award Number R44DK078455. The content is solely the responsibility of the authors and does not necessarily
represent the official views of the National Institutes of Health.” Prior to issuing a press release concerning the outcome
of this research, please notify the NIH awarding IC in advance to allow for coordination.

 

Award recipients must promote objectivity in research
by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under
NIH awards will be free from bias resulting from an Investigator’s Financial Conflict of Interest (FCOI), in accordance with
42 CFR Part 50 Subpart F. Subsequent to the compliance date of the 2011 revised FCOI regulation (i.e., on or before August 24,
2012), Awardees must be in compliance with all aspects of the 2011 revised regulation; until then, Awardees must comply with the
1995 regulation. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does
not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the
NIH website http://grants.nih.gov/grants/policy/coi/ for a link to the regulation and additional important information.

 

If you have any questions about this award, please
contact the individual(s) referenced in Section IV.

 

Sincerely yours,

 

CAROLYN KOFA

Grants Management Officer

NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND
KIDNEY DISEASES

 

	1	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

 

    	 

    	 

    

  

Additional information follows

 

	 	2	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

  

    	 

    	 

    

 

	 	SECTION I – AWARD DATA – 5R44DK078455-03

 

	Award
    Calculation (U.S. Dollars)	 	 	 
	 	 	 	 
	Federal Direct Costs	 	$	[***]	 
	Federal F&A Costs	 	$	[***]	 
	Approved Budget	 	$	[***]	 
	Fee	 	$	[***]	 
	Federal Share	 	$	[***]	 
	TOTAL
    FEDERAL AWARD AMOUNT	 	$	664,710	 
	 	 	 	 	 
	AMOUNT OF THIS ACTION
    (FEDERAL SHARE)	 	$	664,710	 

 

	SUMMARY
    TOTALS FOR ALL YEARS	 
	YR	 	THIS
    AWARD	 	 	CUMULATIVE
    TOTALS	 
	3	 	$	664,710	 	 	$	664,710	 

 

	Fiscal Information:	 
	CFDA Number:	93.847
	EIN:	1113430072A1
	Document Number:	RDK078455B
	Fiscal Year:	2012

 

	IC	 	CAN	 	2012	 
	DK	 	8469933	 	$	664,710	 

 

NIH Administrative Data:

PCC: KMM KSB / OC: 414E / Processed:
KOFAC 03/27/2012

 

	 	SECTION II – PAYMENT/HOTLINE INFORMATION – 5R44DK078455-03

 

For payment and HHS Office of Inspector General
Hotline information, see the NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm

 

	 	SECTION III – TERMS AND CONDITIONS – 5R44DK078455-03

 

This award is based on the application submitted
to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly
or by reference in the following:

 

		a.	The grant program legislation and program regulation cited
in this Notice of Award.

		b.	Conditions on activities and expenditure of funds in other
statutory requirements, such as those included in appropriations acts.

		c.	45 CFR Part 74 or 45 CFR Part 92 as applicable.

		d.	The NIH Grants Policy Statement, including addenda in effect
as of the beginning date of the budget period.

		e.	This award notice, INCLUDING THE TERMS AND CONDITIONS CITED
BELOW.

 

(See NIH Home Page at ‘http://grants.nih.gov/grants/policy/awardconditions.htm’
for certain references cited above.)

 

An unobligated balance may be carried over into
the next budget period without Grants Management Officer prior approval.

 

This grant is subject to Streamlined Noncompeting
Award Procedures (SNAP).

 

This award is subject to the requirements of 2 CFR
Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration
in the Central Contractor Registration. Should a consortium/subaward
be issued under this award, a DUNS requirement must be included. See  http://grants.nih.gov/grants/policy/awardconditions.htm
for the full NIH award term implementing this requirement and other additional information.

 

	 	3	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

 

    	 

    	 

    

 

This award is not subject to the Transparency Act
subaward and executive compensation reporting requirement of 2 CFR Part 170.

 

In accordance with P.L. 110-161, compliance with
the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: 
http://publicaccess.nih.gov/.

 

This award provides support for one or more clinical
trials. By law (Title VIII, Section 801 of Public Law 110-85), the “responsible party” must register
“applicable clinical trials” on the  ClinicalTrials.gov Protocol Registration System
Information Website. NIH encourages registration of all trials whether required under the law or not. For more information,
see  http://grants.nih.gov/ClinicalTrials_fdaaa/

 

This award represents the final year of the competitive
segment for this grant. Therefore, see the NIH Grants Policy Statement Section 8.6 Closeout for closeout requirements at: 
http://grants.nih.gov/grants/policy/#gps .

 

A final Federal Financial Report (FFR) (SF 425)
must be submitted through the eRA Commons (Commons) within 90 days of the expiration date; see the NIH Grants Policy Statement
Section 8.6.1 Financial Reports, http://grants.nih.gov/grants/policy/#gps, for additional information on this submission
requirement. The final FFR must indicate the exact balance of unobligated funds and may not reflect any unliquidated obligations.
There must be no discrepancies between the final FFR expenditure data and the Payment Management System’s (PMS) cash transaction
data.

 

A Final Invention Statement and Certification form
(HHS 568), (not applicable to training, construction, conference or cancer education grants) must be submitted through the eRA
Commons (Commons) within 90 days of the expiration date.

 

Furthermore, unless an application for competitive
renewal is submitted, a final progress report must also be submitted within 90 days of the expiration date. Institute/Centers may
accept the progress report contained in competitive renewal (type 2) in lieu of a separate final progress report. Contact the awarding
IC for IC-specific policy regarding acceptance of a progress report contained in a competitive renewal application in lieu of a
separate final progress report.

 

NIH strongly encourages electronic submission of
the final progress report and the final invention statement through the Closeout feature in the Commons. If the final progress
report and final invention statement are not submitted through the Commons, a copy can be emailed or sent to the contacts listed
below. Copies of the HHS 568 form may be downloaded at:  http://grants.nih.gov/grants/forms.htm.

 

Submissions of the final progress report and HHS
568 may be e-mailed as PDF attachments to the NIH Central Closeout Center at: DeasCentralized@od.nih.gov.

 

Paper submissions of the final progress report and
the HHS 568 may be faxed to the NIH Central Closeout Center at 301-480-2304 or mailed to the NIH Central Closeout Center at the
following address:

 

NIH/OD/OER/DEAS

Central Closeout Center

6705 Rockledge Drive, Room 2207

Bethesda, MD 20892-7987 (for regular or U.S. Postal
Service Express mail) 

Bethesda, MD 20817 (for other courier/express mail delivery only)

 

The final progress report should include, at a minimum,
a summary of progress toward the achievement of the originally stated aims, a list of significant results (positive and/or negative),
a list of publications and the grant number. If human subjects were included in the research, the final progress report should
also address the following:

 

Report on the inclusion of gender and minority study
subjects (using the gender and minority Inclusion Enrollment Form as provided in the PHS 2590 and available at 
http://grants.nih.gov/grants/forms.htm).

 

Where appropriate, indicate whether children were
involved in the study or how the study was relevant for conditions affecting children (see NIH Grants Policy Statement Section
4.1.15.7

 

	 	4	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

    	 

    	 

    

  

Inclusion of Children as Subjects in Clinical Research
at URL  http://grants.nih.gov/grants/policy/#gps).

 

Describe any data, research materials (such as cell
lines, DNA probes, animal models), protocols, software, or other information resulting from the research that is available to be
shared with other investigators and how it may be accessed.

 

Any other specific requirements set forth in the
terms and conditions of the award must also be addressed in the final progress report.

 

Note, if this is the final year of a competitive
segment due to the transfer of the grant to another institution, then not all the requirements stated above are applicable. Specifically
a Final Progress Report is not required. However, a final FFR is required and should be submitted electronically as noted above.
In addition, if not already submitted, the Final Invention Statement is required and should be sent directly the assigned Grants
Management Specialist.

 

Treatment of Program Income:

Additional Costs

 

	 	SECTION IV – DK Special Terms and Conditions – 5R44DK078455-03

 

This award is issued in accordance with the NIH 2012
fiscal policies described in the NIH Guide Notice NOT-OD-12-036: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-12-036.html

 

The grantee is required to follow the data and safety
monitoring plan submitted with the “Just-In- Time” documentation dated December 17, 2010, and may not implement any changes
in the plan without the written prior approval of the NIDDK.

 

This study/clinical trial has been identified for
inclusion in ClinicalTrials.gov. The U.S. National Institutes of Health (NIH), through its National Library of Medicine (NLM),
has developed this site in collaboration with all NIH Institutes and the Food and Drug Administration (FDA). The Principal Investigator (PI) will shortly receive
account information and instructions that will allow you to enter your study information into ClinicalTrials.gov. As soon as you
have an approved protocol the information should be entered. It is the grantee/PI’s responsibility to update it as changes in the
protocol and study contacts occur. It is required that the information entered in ClinicalTrials.gov be reviewed at least annually,
even if no changes are necessary.

 

This award includes funds awarded for consortium
activity with Maastricht University Medical Center in the amount of $[***] total cost. Consortiums are to be established and administered
as described in the NIH Grants Policy Statement (NIH GPS). The referenced section of the NIH Grants Policy Statement is available
at http://grants1.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part12.htm#_Toc54600251, pages 224-227.

 

In addition to the PI, the following individuals
are named as key personnel:

Dr. Bermingham

Dr. Goldberg

Dr. Narayan

Dr. Panicker

 

Written prior approval is required if any of the
individual(s) named above withdraws from the project entirely, is absent from the project during any continuous period of 3 months
or more, or reduces time devoted to the project by 25 percent or more from the level that was approved at the time of award.

 

Prior to drawing down funds for this award from
the payment management system, you are required to have in place written policies and procedures for financial and business
management systems. Your systems must comply with the standards
included in the attachment to the letter/email “Requirements for Financial and Business Management Systems Requirements for

 

	 	5	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

 

    	 

    	 

    

 

SBIR/STTR Awardees” which was sent to your
organization’s Business Official on December 3, 2010. The policies and procedures must remain in effect for the duration of this
project.

 

Notice: Under governing regulations, Federal funds
administered by the Department of Health and Human Services shall not be expended for research involving human subjects, and individuals
shall not be enrolled in such research, without prior approval by the Office of Human Research Protections (OHRP) of an assurance
to comply with the requirements of 45 CFR 46 to protect human research subjects. This restriction applies to all collaborating
sites without OHRP- approved assurances, whether domestic or foreign, and compliance must be ensured by the awardee.

 

Notice: Under governing policy, Federal funds administered
by the National Institutes of Health (NIH) shall not be expended for research involving live vertebrate animals without prior approval
by the Office for Laboratory Animal Welfare (OLAW) of an assurance to comply with the NIH policy on humane care and use of laboratory
animals. This restriction applies to all performance sites (e.g., collaborating institutions, subcontractors, subgrantees) without
OLAW-approved assurances, whether domestic or foreign.

 

The fee provided as part of this Notice of Award
is in addition to the allowable direct and facilities and administrative costs. An adjustment of the fee will be made in the event
the grant is terminated. The fee should be drawn down from the DHHS Payment Management System (PMS) in increments proportionate
to the draw down of costs. Questions concerning access to the PMS should be directed to (877) 614-5533.

 

Allowable costs of activities
conducted by for-profit organizations will be determined by applying the cost principles of the Federal Acquisition Regulation
set forth in 48 CFR, Subpart 31.2. (see http://www.access.gpo.gov/nara/cfr/waisidx_01/48cfr31_01.html)

 

Intellectual property rights: Normally, the awardee
organization retains the principal worldwide patent rights to any invention developed with United States government support. Under
Title 37 Code of Federal Regulations Part 401, the government receives a royalty free license for its use, reserves the right to
require the patent holder to license others in certain circumstances, and requires that anyone exclusively licensed to sell the
invention in the United States must normally manufacture it substantially in the United States.

 

Rights and obligations related to inventions created
or reduced to practice as a result of this award are detailed in 35 U.S.C. 205 and 37 CFR Part 401. These inventions must be reported
to the Division of Extramural Invention and Technology Resources, OPERA, NIH, 6705 Rockledge Drive, MSC 7980, Room 310, Bethesda,
MD 20892-7980, (301) 435-1986. For additional information, access the NIH link on the interagency Edison web site (www.iedison.gov)
which includes an electronic invention reporting system, reference information and the text to 37 CFR 401.

 

To the extent authorized by 35 U.S.C., Section 205,
the government will not make public any information disclosing an NIH-supported invention for a 4-year period to allow the awardee
organization a reasonable time to file a patent application, nor will the government release any information that is part of that
patent application.

 

Prior approval to implement budgetary and programmatic
changes, where required by NIH Policy, (See the NIH Grants Policy Statement for prior approval requirements at: http://grants.nih.gov/grants/policy/nihgps_2010/nihgps_ch8.htm)
must be obtained in writing from the Grants Management contact shown on this Notice of Award. A letter signed by the Principal
Investigator and a Business Official of the Grantee Institution, and should include an explanation and justification for the action(s).
Requests may be made via e-mail provided they are routed through these same officials. If there are questions as to whether an
action requires prior approval, contact the Grants Management Specialist.

 

The grantee is required to establish a positive time
and effort reporting system.

 

As mentioned in Section III above, this award represents
the final year of the competitive segment for this grant. In addition to the instructions outlined in Section III, please follow
the guidelines here for submission of the Final Progress Report.

 

	 	6	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

    	 

    	 

    

 

There is no ‘form page’ for a Final Report. The Final
Progress Report may be typed on plain white paper (or you may use the PHS 398 Continuation Page). The recommended length for the
narrative portion is 10 pages.

 

STAFF CONTACTS

 

The Grants Management Specialist is responsible for
the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions.
The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work
together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should
be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

 

Grants Management Specialist: Pamela Love

Email: lovepa@mail.nih.gov Phone: (301)
435-6198 Fax: (301) 594-9523

 

Program Official: Marva M. Moxey-mims

Email: moxey-mimsm@extra.niddk.nih.gov Phone:
(301) 451-5037 Fax: (301) 480-3510

 

SPREADSHEET SUMMARY

GRANT NUMBER: 5R44DK078455-03

 

INSTITUTION: ANGION BIOMEDICA CORPORATION

 

	Facilities
    and Administrative Costs	 	Year
    3	 
	F&A Cost Rate 1	 	 	90	%
	F&A Cost Base 1	 	$	[***]	 
	F&A Costs 1	 	$	[***]	 

 

	 	7	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}]]